443 related articles for article (PubMed ID: 33227223)
1. A critical review of apomorphine hydrochloride sublingual film for the treatment of Parkinson's disease 'OFF' episodes.
Caughman CY; Factor S
Expert Rev Neurother; 2021 Feb; 21(2):169-177. PubMed ID: 33227223
[No Abstract] [Full Text] [Related]
2. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
Deleu D; Hanssens Y; Northway MG
Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
[TBL] [Abstract][Full Text] [Related]
4. Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease 'OFF' episodes.
Thach A; Zichlin ML; Kirson N; Yang K; Gaburo K; Pappert E; Mehta D; Williams GR
J Comp Eff Res; 2022 Mar; 11(4):285-295. PubMed ID: 35068168
[No Abstract] [Full Text] [Related]
5. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
6. [Inhaled levodopa: from evidence to experience].
Martínez-Castrillo JC; Pareés-Moreno I; López Sendón-Moreno JL; Pérez-Torre P; Fanjul S; Patiño-Patón A; García-Ribas G; Alonso-Cánovas A
Rev Neurol; 2024 Jun; 78(S01):S1-S10. PubMed ID: 38916176
[TBL] [Abstract][Full Text] [Related]
7. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations.
Trenkwalder C; Chaudhuri KR; García Ruiz PJ; LeWitt P; Katzenschlager R; Sixel-Döring F; Henriksen T; Sesar Á; Poewe W; ; Baker M; Ceballos-Baumann A; Deuschl G; Drapier S; Ebersbach G; Evans A; Fernandez H; Isaacson S; van Laar T; Lees A; Lewis S; Martínez Castrillo JC; Martinez-Martin P; Odin P; O'Sullivan J; Tagaris G; Wenzel K
Parkinsonism Relat Disord; 2015 Sep; 21(9):1023-30. PubMed ID: 26189414
[TBL] [Abstract][Full Text] [Related]
8. Sublingual apomorphine in treatment of Parkinson's disease: a review.
Hislop J; Margolesky J; Shpiner DS
Int J Neurosci; 2024 May; 134(5):474-480. PubMed ID: 35986574
[TBL] [Abstract][Full Text] [Related]
9. On-Demand Therapy for OFF Episodes in Parkinson's Disease.
Olanow CW; Poewe W; Rascol O; Stocchi F
Mov Disord; 2021 Oct; 36(10):2244-2253. PubMed ID: 34363424
[TBL] [Abstract][Full Text] [Related]
10. On demand therapy for Parkinson's disease patients: Opportunities and choices.
Hauser RA; LeWitt PA; Comella CL
Postgrad Med; 2021 Sep; 133(7):721-727. PubMed ID: 34082655
[TBL] [Abstract][Full Text] [Related]
11. Inhaled apomorphine in patients with 'on-off' fluctuations: a randomized, double-blind, placebo-controlled, clinic and home based, parallel-group study.
Grosset KA; Malek N; Morgan F; Grosset DG
J Parkinsons Dis; 2013; 3(1):31-7. PubMed ID: 23938309
[TBL] [Abstract][Full Text] [Related]
12. Apomorphine hydrochloride for the treatment of Parkinson's disease.
Unti E; Ceravolo R; Bonuccelli U
Expert Rev Neurother; 2015; 15(7):723-32. PubMed ID: 26037961
[TBL] [Abstract][Full Text] [Related]
13. Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease?
Rota S; Urso D; van Wamelen DJ; Leta V; Boura I; Odin P; Espay AJ; Jenner P; Chaudhuri KR
Transl Neurodegener; 2022 Oct; 11(1):43. PubMed ID: 36229860
[TBL] [Abstract][Full Text] [Related]
14. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
Stacy M; Silver D
Parkinsonism Relat Disord; 2008; 14(2):85-92. PubMed ID: 18083605
[TBL] [Abstract][Full Text] [Related]
15. Apomorphine Sublingual Film Compared with Subcutaneous Apomorphine for OFF Episodes in Parkinson's Disease: An Open-Label, Randomized, Crossover Study.
Stocchi F; Rascol O; Poewe W; Chaudhuri KR; Kassubek J; Lopez Manzanares L; Zhang Y; Bowling A; Pappert E; Wu S;
J Parkinsons Dis; 2023; 13(8):1329-1342. PubMed ID: 37980683
[TBL] [Abstract][Full Text] [Related]
16. Apomorphine hydrochloride: a sublingual tablet for the OFF episodes in Parkinson's disease.
Paton DM
Drugs Today (Barc); 2021 Jan; 57(1):5-16. PubMed ID: 33594386
[TBL] [Abstract][Full Text] [Related]
17. Apomorphine for Parkinson's disease: pharmacologic and clinical considerations.
Wagner MJ; Daniel CP; Plaisance CJ; Borne GE; Ahmadzadeh S; Shekoohi S; Kaye AD
Expert Opin Emerg Drugs; 2023 Dec; 28(4):275-281. PubMed ID: 37909462
[TBL] [Abstract][Full Text] [Related]
18. Motor response with apomorphine sublingual film and levodopa in patients with OFF episodes.
Isaacson SH; Bowling A; Zhang I; Pappert E; Stocchi F;
Neurodegener Dis Manag; 2023 Apr; 13(2):75-84. PubMed ID: 36562349
[No Abstract] [Full Text] [Related]
19. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.
Hauser RA; Olanow CW; Dzyngel B; Bilbault T; Shill H; Isaacson S; Dubow J; Agro A
Mov Disord; 2016 Sep; 31(9):1366-72. PubMed ID: 27430123
[TBL] [Abstract][Full Text] [Related]
20. Apomorphine therapy in Parkinson's disease: a review.
Haq IU; Lewitt PA; Fernandez HH
Expert Opin Pharmacother; 2007 Nov; 8(16):2799-809. PubMed ID: 17956200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
